Skip to main content Help with accessibility Skip to main navigation

Insulin Glargine Biosimilar

Indication

Type 1 and Type 2 diabetes mellitus
Green

Brand:

Abasaglar®

Nice TA:

Commissioning responsibility:

CCG

PbR excluded:

No

BNF chapter:
Endocrine system

Background

Must be commenced by a healthcare professional who is appropriately trained and experienced in the initiation of insulin.
Biosimilars of insulin glargine 100 units/mL (Lantus®) are recommended for use in patients with type 1 and type 2 diabetes mellitus. The prescribing of biosimilar preparations should be by brand name, followed by the concentration and recommended daily dose in units and a statement of the formulation. Treatment should normally be started with the least expensive drug.
The initiation of biosimilar insulins should be in NEW patients or patients assessed to need a medication change, with close monitoring of their blood glucose to ensure good control is achieved.
The LSCMMG recommends Abasaglar KwikPen® as the 1st line long-acting insulin analogue.

Recommendation

LSCMMG Recommendation:

Green

Reason for decision:

Suitable for initiation in primary care

Decisions of Lancashire local decision making groups

Green
Green
Amber 0
Green
Green
Amber 0
Green
Green
What do the colours mean?

Last Updated: 01 - Jan - 2016